Literature DB >> 25653191

Adenosine 2A receptor agonism: A single intrathecal administration attenuates motor paralysis in experimental autoimmune encephalopathy in rats.

Lisa C Loram1, Keith A Strand2, Frederick R Taylor2, Evan Sloane2, Anne-Marie Van Dam3, Jayson Rieger4, Steven F Maier2, Linda R Watkins2.   

Abstract

A single intrathecal dose of adenosine 2A receptor (A2AR) agonist was previously reported to produce a multi-week reversal of allodynia in two different models of neuropathic pain in addition to downregulating glial activation markers in the spinal cord. We aimed to determine whether a single intrathecal administration of an A2AR agonist was able to attenuate motor symptoms induced by experimental autoimmune encephalopathy. Two A2AR agonists (CGS21680 and ATL313) significantly attenuated progression of motor symptoms following a single intrathecal administration at the onset of motor symptoms. OX-42, a marker of microglial activation, was significantly attenuated in the lumbar spinal cord following A2AR administration compared to vehicle. Therefore, A2AR agonists attenuate motor symptoms of EAE by acting on A2AR in the spinal cord.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATL313; CGS21680; Multiple sclerosis; Myelin oligodendrocyte glycoprotein

Mesh：

Substances：

Year:  2015        PMID： 25653191      PMCID： PMC4447711          DOI： 10.1016/j.bbi.2015.01.014

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN： 0889-1591            Impact factor:   7.217


  24 in total

Review 1.  Diagnostic and prognostic potential of the macrophage specific receptor CD163 in inflammatory diseases.

Authors:  Christa Buechler; Kristina Eisinger; Sabrina Krautbauer
Journal:  Inflamm Allergy Drug Targets       Date:  2013-12

Review 2.  Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury.

Authors:  Shuang-Shuang Dai; Yuan-Guo Zhou
Journal:  Rev Neurosci       Date:  2011       Impact factor: 4.353

3.  Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats.

Authors:  Guo Qian Chen; Yan Yan Chen; Xin Shi Wang; Sai Zhen Wu; Hui Min Yang; Hui Qin Xu; Jin Cai He; Xiao Tong Wang; Jiang Fan Chen; Rong Yuan Zheng
Journal:  Brain Res       Date:  2009-10-29       Impact factor: 3.252

4.  Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain.

Authors:  Lisa C Loram; Jacqueline A Harrison; Evan M Sloane; Mark R Hutchinson; Paige Sholar; Frederick R Taylor; Debra Berkelhammer; Benjamen D Coats; Stephen Poole; Erin D Milligan; Steven F Maier; Jayson Rieger; Linda R Watkins
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

5.  Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism.

Authors:  Tan Wang; Na-na Xi; Yu Chen; Xiao-feng Shang; Qiang Hu; Jiang-fan Chen; Rong-yuan Zheng
Journal:  Neuropharmacology       Date:  2014-07-11       Impact factor: 5.250

6.  Intrathecal injection of adenosine 2A receptor agonists reversed neuropathic allodynia through protein kinase (PK)A/PKC signaling.

Authors:  Lisa C Loram; Frederick R Taylor; Keith A Strand; Jacqueline A Harrison; Rachael Rzasalynn; Paige Sholar; Jayson Rieger; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2013-06-28       Impact factor: 7.217

7.  The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling.

Authors:  Christopher James Ferrante; Grace Pinhal-Enfield; Genie Elson; Bruce Neil Cronstein; Gyorgy Hasko; Shalini Outram; Samuel Joseph Leibovich
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

8.  Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy.

Authors:  Evan Sloane; A Ledeboer; W Seibert; B Coats; M van Strien; S F Maier; K W Johnson; R Chavez; L R Watkins; L Leinwand; E D Milligan; A M Van Dam
Journal:  Brain Behav Immun       Date:  2008-09-20       Impact factor: 7.217

Review 9.  Exploring the full spectrum of macrophage activation.

Authors:  David M Mosser; Justin P Edwards
Journal:  Nat Rev Immunol       Date:  2008-12       Impact factor: 53.106

10.  An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models.

Authors:  Christopher C Moore; Edward N Martin; Grace H Lee; Tom Obrig; Joel Linden; W Michael Scheld
Journal:  BMC Infect Dis       Date:  2008-10-20       Impact factor: 3.090
View more
  6 in total

1.  Adenosine Promotes the Recovery of Mice from the Cuprizone-Induced Behavioral and Morphological Changes while Effecting on Microglia and Inflammatory Cytokines in the Brain.

Authors:  Jinling Zhang; Liu Yang; Zeman Fang; Jiming Kong; Qingjun Huang; Haiyun Xu
Journal:  J Neuroimmune Pharmacol       Date:  2018-08-01       Impact factor: 4.147

Review 2.  The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis.

Authors:  Elham Safarzadeh; Farhad Jadidi-Niaragh; Morteza Motallebnezhad; Mehdi Yousefi
Journal:  Inflamm Res       Date:  2016-03-09       Impact factor: 4.575

3.  Behavioral assessment of neuropathic pain, fatigue, and anxiety in experimental autoimmune encephalomyelitis (EAE) and attenuation by interleukin-10 gene therapy.

Authors:  Peter M Grace; Lisa C Loram; John P Christianson; Keith A Strand; Johanna G Flyer-Adams; Kathryn R Penzkover; John R Forsayeth; Anne-Marie van Dam; Melissa J Mahoney; Steven F Maier; Raymond A Chavez; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2016-05-14       Impact factor: 7.217

4.  Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone.

Authors:  Andrew J Kwilasz; Laurel S Todd; Julissa C Duran-Malle; Anouk E W Schrama; Eric H Mitten; Tracey A Larson; Madison A Clements; Kevin M Harris; Scott T Litwiler; Xiaohui Wang; Anne-Marie Van Dam; Steven F Maier; Kenner C Rice; Linda R Watkins; Ruth M Barrientos
Journal:  Behav Brain Res       Date:  2020-09-06       Impact factor: 3.332

5.  Toll-like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain.

Authors:  Andrew J Kwilasz; Suzanne M Green Fulgham; Julissa Chante Duran-Malle; Anouk E W Schrama; Eric H Mitten; Laurel S Todd; Hardik P Patel; Tracey A Larson; Madison A Clements; Kevin M Harris; Scott T Litwiler; Lewis O Harvey; Steven F Maier; Raymond A Chavez; Kenner C Rice; Anne-Marie Van Dam; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2021-01-07       Impact factor: 7.217

Review 6.  The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis.

Authors:  Eduardo Duarte-Silva; Henning Ulrich; Ágatha Oliveira-Giacomelli; Hans-Peter Hartung; Sven G Meuth; Christina Alves Peixoto
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.